These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35843589)

  • 1. Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk.
    Kuchay MS; Martínez-Montoro JI; Kaur P; Fernández-García JC; Ramos-Molina B
    Ageing Res Rev; 2022 Sep; 80():101696. PubMed ID: 35843589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.
    Armandi A; Rosso C; Caviglia GP; Ribaldone DG; Bugianesi E
    Front Endocrinol (Lausanne); 2021; 12():716533. PubMed ID: 34858322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle.
    Poggiogalle E; Donini LM; Lenzi A; Chiesa C; Pacifico L
    World J Gastroenterol; 2017 Mar; 23(10):1747-1757. PubMed ID: 28348479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.
    Iwaki M; Kobayashi T; Nogami A; Saito S; Nakajima A; Yoneda M
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
    Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
    Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).
    Lee YH; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH
    Hepatology; 2016 Mar; 63(3):776-86. PubMed ID: 26638128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia and fatty liver disease.
    Kim JA; Choi KM
    Hepatol Int; 2019 Nov; 13(6):674-687. PubMed ID: 31705444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease.
    Rigor J; Vasconcelos R; Lopes R; Moreira T; Barata P; Martins-Mendes D
    Minerva Gastroenterol (Torino); 2023 Sep; 69(3):374-381. PubMed ID: 35343663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey.
    Moon JH; Koo BK; Kim W
    J Cachexia Sarcopenia Muscle; 2021 Aug; 12(4):964-972. PubMed ID: 34080327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Roles of Non-Pharmacologic and Emerging Pharmacologic Management of Non-alcoholic Fatty Liver Disease and Sarcopenia: A Narrative Review.
    Rivera FB; Adizas A; Cubarrubias D; Bantayan NR; Choi S; Carado GP; Yu MG; Lerma E; Vijayaraghavan K
    J ASEAN Fed Endocr Soc; 2024; 39(1):84-94. PubMed ID: 38863907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
    Mikolasevic I; Pavic T; Kanizaj TF; Bender DV; Domislovic V; Krznaric Z
    Can J Gastroenterol Hepatol; 2020; 2020():8859719. PubMed ID: 33204675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.
    Bhanji RA; Narayanan P; Allen AM; Malhi H; Watt KD
    Hepatology; 2017 Dec; 66(6):2055-2065. PubMed ID: 28777879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution.
    Alferink LJM; Trajanoska K; Erler NS; Schoufour JD; de Knegt RJ; Ikram MA; Janssen HLA; Franco OH; Metselaar HJ; Rivadeneira F; Darwish Murad S
    J Bone Miner Res; 2019 Jul; 34(7):1254-1263. PubMed ID: 31074909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA.
    Wijarnpreecha K; Kim D; Raymond P; Scribani M; Ahmed A
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1121-1128. PubMed ID: 30888971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?
    De Fré CH; De Fré MA; Kwanten WJ; Op de Beeck BJ; Van Gaal LF; Francque SM
    Obes Rev; 2019 Feb; 20(2):353-363. PubMed ID: 30474288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study.
    Roh E; Hwang SY; Yoo HJ; Baik SH; Lee JH; Son SJ; Kim HJ; Park YS; Lee SG; Cho BL; Jang HC; Kim BJ; Kim M; Won CW; Choi KM
    Hepatol Int; 2022 Jun; 16(3):545-554. PubMed ID: 34780030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Cai C; Song X; Chen Y; Chen X; Yu C
    Hepatol Int; 2020 Jan; 14(1):115-126. PubMed ID: 31290072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease.
    Giri S; Anirvan P; Angadi S; Singh A; Lavekar A
    World J Gastrointest Pathophysiol; 2024 Apr; 15(1):91100. PubMed ID: 38682026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.